Jonathan Barrett MacKenzie's most recent trade in Medifast Inc was a trade of 7,671 Common Stock done . Disclosure was reported to the exchange on March 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2025 | 7,671 | 11,138 (0%) | 0% | 0 | Common Stock | |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.87 per share. | 13 Mar 2025 | 280 | 3,626 (0%) | 0% | 13.9 | 3,884 | Common Stock |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.35 per share. | 13 Mar 2025 | 99 | 3,467 (0%) | 0% | 14.4 | 1,421 | Common Stock |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.93 per share. | 13 Mar 2025 | 60 | 3,566 (0%) | 0% | 13.9 | 836 | Common Stock |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.91 per share. | 13 Sep 2024 | 11 | 3,906 (0%) | 0% | 18.9 | 208 | Common Stock |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.61 per share. | 15 Mar 2024 | 83 | 3,917 (0%) | 0% | 36.6 | 3,039 | Common Stock |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.61 per share. | 15 Mar 2024 | 51 | 4,000 (0%) | 0% | 36.6 | 1,867 | Common Stock |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2024 | 2,565 | 4,051 (0%) | 0% | 0 | Common Stock | |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.10 per share. | 13 Sep 2023 | 10 | 1,486 (0%) | 0% | 81.1 | 811 | Common Stock |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 906 | 1,496 (0%) | 0% | 0 | Common Stock | |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 104.46 per share. | 16 Mar 2023 | 57 | 590 (0%) | 0% | 104.5 | 5,954 | Common Stock |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 124.60 per share. | 13 Sep 2022 | 10 | 647 (0%) | 0% | 124.6 | 1,246 | Common Stock |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2022 | 548 | 657 (0%) | 0% | 0 | Common Stock | |
| Medifast Inc | Jonathan Barrett MacKenzie | VP, Finance & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2021 | 109 | 109 (0%) | 0% | 0 | Common Stock |